---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-021918"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:27:25.576309+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Supernus enters into $150M secured credit facility with UBS

## Summary
- Up to $150M revolving credit line for general corporate purposes, secured by investment accounts held at UBS.
- Borrowings bear interest at UBS Fixed or Variable Funding Rate plus applicable spread.
- Uncommitted demand facility; UBS can demand repayment and terminate at any time without cause.
- CEO Jack Khattar stated the credit line strengthens balance sheet flexibility.

## SEC filing metadata
- accession: 0001104659-23-021918
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000110465923021918/0001104659-23-021918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000110465923021918/tm235504d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-021918
- JSON: https://secwatch.observer/filing/0001104659-23-021918.json
- Plain text: https://secwatch.observer/filing/0001104659-23-021918.txt

## Key facts
- Debt Financings
  SUPERNUS PHARMACEUTICALS, INC. incurred revolving credit of up to $150,000,000.00 with UBS Bank USA at Fixed rate: UBS Fixed Funding Rate + applicable Percentage Spread; Variable rate maturing Not explicitly stated; payable on demand or upon default.
  - Instrument: revolving credit
  - Principal: up to $150,000,000.00
  - Counterparty: UBS Bank USA
  - Rate: Fixed rate: UBS Fixed Funding Rate + applicable Percentage Spread; Variable rate
  - Maturity: Not explicitly stated; payable on demand or upon default
  - Event: incurrence
  source text: On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00, which can be drawn at any time and will be used for general corporate purposes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000110465923021918/0001104659-23-021918-index.htm
- Material Agreements
  SUPERNUS PHARMACEUTICALS, INC. entered into Credit Line with UBS Bank USA valued at $150,000,000.00 (effective 2023-02-08).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: UBS Bank USA
  - Value: $150,000,000.00
  - Effective: 2023-02-08
  source text: On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000110465923021918/0001104659-23-021918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.